Lv11
48 积分 2024-06-13 加入
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
3小时前
已完结
The efficacy and safety of cadonilimab after first anti-PD-1 failure in the treatment of recurrent endometrial and cervical carcinoma: A retrospective, real-world study
11天前
已完结
Colorectal cancer immunotherapy-Recent progress and future directions
3个月前
已完结
Medical Image Synthesis via Deep Learning
9个月前
已完结
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
1年前
已完结
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146
1年前
已完结
皖公网安备34019202002308
